About FairPark II

About Fair Park II

What is FAIR PARK II? What is Parkinson’s Disease? What is iron chelation?

Who is involved in Fair Park II?


Who is involved? Who are the patients? Can I get involved?

Fair Park II Progress


Find out how we are getting on with the study through our regular updates


The first patient has been enrolled at Lille's Hospital on February 9th 2016

The FAIR PARK II annual meeting was held in Berlin, Germany on June 23rd and 24th 2016

The FAIR-PARK II kick-off meeting was held in Lille, France on 4-5 May 2015

The final list of European expert centres for the clinical trial will be available in October 2015

The final version of the study protocol, as submitting to regulators and ethics committees, will be available in January 2016.

Patient Recruitment Countdown

19th December 2016

Patients to be recruited


Patients recruited


Get the latest updates via our feeds

 Get the latest updates via our feed

Subscribe to our newsletters

Subscribe to our newsletters

Contact us

 Contact us info@fairpark2.eu


Conservative iron chelation as a disease modifying strategy in Parkinson’s disease: a multicentric, parallel-group, placebo-controlled, randomised clinical trial of deferiprone

Latest News Articles

Contact Us


Scientific Coordinator: Prof David Devos
Project Manager (CHRUL): Pauline Guyon pauline.guyon@chru-lille.fr
Senior Project Manager (IT): Delphine Smagghe delphine.smagghe@inserm-transfert.fr
Project Manager (IT): Stephanie Le Naour stephanie.lenaour@inserm-transfert.fr


Centre Hospitalier Regional et Universitaire de Lille (CHRUL), 2 avenue Oscar Lambret - 59037 Lille Cedex
Inserm-Transfert (IT), 7 rue de Watt - 75013 Paris, France


Paris Inserm Transfert

Go to top